Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Clinics ; 70(12): 775-780, Dec. 2015. tab, graf
Artigo em Inglês | LILACS | ID: lil-769705

RESUMO

OBJECTIVE: The role of chemotherapy in treating advanced thymic carcinoma is unclear. The purpose of the current study was to investigate the efficacy of chemotherapy and the prognostic factors for patients with advanced thymic carcinoma. METHODS: A retrospective review of the medical records of 86 patients treated with chemotherapy for advanced thymic carcinoma was conducted between 2000 and 2012 at our institution. The clinical characteristics, chemotherapy regimens and prognostic factors were analyzed. Survival curves were plotted using the Kaplan-Meier method and the Cox proportional hazard model was used for multivariate analysis. RESULTS: Of the 86 patients, 56 were male and 30 were female. The median survival time was 24.5 months. For the first-line chemotherapy treatment, the objective response rate was 47.7% and the disease control rate was 80.2%. The median progression-free survival for all patients was 6.5 months for first-line chemotherapy. No significant differences in progression-free survival were observed among the different chemotherapy regimens. Multivariate analyses revealed that the prognostic factors for overall survival included performance status (p=0.043), histology grade (p=0.048), and liver metastasis (p=0.047). CONCLUSION: Our results suggest that there is no difference in efficacy between multiagent and doublet regimens. The prognosis of patients with advanced thymic carcinoma can be predicted based on histological grade, liver metastasis and performance status.


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Antineoplásicos/uso terapêutico , Timoma/tratamento farmacológico , Neoplasias do Timo/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Estimativa de Kaplan-Meier , Neoplasias Hepáticas/secundário , Prognóstico , Estudos Retrospectivos , Fatores de Tempo , Resultado do Tratamento , Timoma/mortalidade , Timoma/patologia , Neoplasias do Timo/mortalidade , Neoplasias do Timo/patologia
2.
Korean Journal of Radiology ; : 360-363, 2007.
Artigo em Inglês | WPRIM | ID: wpr-17112

RESUMO

A malignant tumor is generally believed to be very unlikely to metastasize to the thymus. Only three cases of thymic metastases have been reported so far in the medical literature. We report here a rare case of metastatic breast cancer to the thymus, which was detected by CT and PET scanning, and the metastasis was also confirmed by video-assisted thoracic surgery biopsy. Recognition of an unusual breast cancer metastasis, such as to the thymus, as well as the usual patterns of breast cancer metastasis will facilitate an accurate, prompt diagnosis and its appropriate treatment.


Assuntos
Adulto , Feminino , Humanos , Antineoplásicos Fitogênicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Carcinoma Ductal de Mama/tratamento farmacológico , Paclitaxel/uso terapêutico , Neoplasias do Timo/tratamento farmacológico
3.
Indian J Cancer ; 1999 Mar; 36(1): 46-56
Artigo em Inglês | IMSEAR | ID: sea-49925

RESUMO

Invasive thymomas comprise 0.1%-0.2% of all malignancies in India. This report is an audit of 11 cases (10 males and 1 female) at a mean age of 36.6 years (range 25-52 years) of invasive thymoma accrued over an eight year period treated by combined modality treatment. Nine of these presented with myaesthenia gravis. All patients underwent initial surgery (3 partial and 8 total resections) and postoperative radiotherapy. Two of the three partially resected patients received one course of chemotherapy prior to radiotherapy consisting of cyclophosphamide, vincristine, procarbazine and prednisolone. At a median follow up of 28 months (range 2-87) there have been no local relapses, one distant metastasis and one death due to uncontrolled myaesthenia. The treatment strategies with invasive thymomas would depend upon the extent of resection. Postoperative radiotherapy appears to be indicated in all cases, however the role of chemotherapy may be limited to those with partial resection.


Assuntos
Adulto , Antineoplásicos/administração & dosagem , Antineoplásicos Alquilantes/administração & dosagem , Antineoplásicos Hormonais/administração & dosagem , Antineoplásicos Fitogênicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Causas de Morte , Radioisótopos de Cobalto/uso terapêutico , Terapia Combinada , Ciclofosfamida/administração & dosagem , Feminino , Seguimentos , Humanos , Índia , Masculino , Auditoria Médica , Pessoa de Meia-Idade , Miastenia Gravis/etiologia , Invasividade Neoplásica , Prednisolona/administração & dosagem , Procarbazina/administração & dosagem , Compostos Radiofarmacêuticos/uso terapêutico , Timectomia , Timoma/tratamento farmacológico , Neoplasias do Timo/tratamento farmacológico , Vincristina/administração & dosagem
4.
Medical Journal of the Islamic Republic of Iran. 1993; 7 (1): 43-6
em Inglês | IMEMR | ID: emr-29314

RESUMO

In this study the effect of the alkylating agent, sulfur mustard, on calf thymus chromatin was investigated using UV/V is spectroscopy, gel electrophoresis and thermal denaturation techniques. The results show that treatment of isolated chromatin with sulfur mustard releases histones from the core particles but does not affect histone H1and nonhistone chromosomal proteins. The content of released proteins for the amounts lower than 50ug/ml are both dose and time dependent. It is suggested that they have cross linked reaction to other chromosomal proteins or to DNA. Thermal melting analysis also indicate that the interaction of sulfur mustard with DNA increases thermal melt[TM] of DNA revealing condensation of DNA molecule by sulfur mustard. The results in relation to the functional states of chromatin are discussed


Assuntos
Neoplasias do Timo/tratamento farmacológico , Gás de Mostarda , Alquilantes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA